: Drug firm Cadila Healthcare
on Monday said it has received an establishment inspection report (EIR) for its Baddi manufacturing plant from the US Food and Drug Administration after successful inspection closure.
The company's "manufacturing plant at Baddi, Himachal Pradesh, has successfully obtained the Establishment Inspection Report from the United States Food and Drug Administration (FDA)", Cadila Healthcare said in a filing to the BSE.
This will now pave the way for further approval of products from this site, it added. The company makes formulations at the Baddi manufacturing facility.
An establishment inspection report is given to an establishment after completion of inspection by the US health regulator .
At 1:26 p.m., shares in Cadila Healthcare
were trading 2.26 per cent higher at Rs 317.10 apiece on the BSE, whose benchmark Sensex index was down 0.65 per cent.